Literature DB >> 15801032

Bone mineral density in children and adolescents with systemic lupus erythematosus, juvenile dermatomyositis, and systemic vasculitis: relationship to disease duration, cumulative corticosteroid dose, calcium intake, and exercise.

Khayriah A Alsufyani1, Olivia Ortiz-Alvarez, David A Cabral, Lori B Tucker, Ross E Petty, Helen Nadel, Peter N Malleson.   

Abstract

OBJECTIVE: To describe the frequency of abnormal bone mineralization in a population of children with juvenile systemic lupus erythematosus (JSLE), juvenile dermatomyositis (JDM), and systemic vasculitis; and to investigate the relationship of bone mineral density (BMD) to cumulative corticosteroid dose, disease duration, Tanner stage, calcium intake, and exercise in these patients.
METHODS: A retrospective chart review of children attending the pediatric rheumatology clinic at British Columbia's Children's Hospital was conducted to obtain demographic data (sex, ethnicity, disease duration, cumulative corticosteroid dose, and mean daily corticosteroid dose). All patients had at least one BMD measurement by dual energy x-ray absorptiometry (DEXA) at lumbar spine, hip, and total body. BMD was expressed as g/cm2 and Z scores; an abnormal Z score was defined as </= -1.5. Daily calcium intake was calculated. Physical activity was scored using a validated 7 day physical activities questionnaire.
RESULTS: A total of 36 patients were studied. Twenty-five patients had SLE, 7 had JDM, and 4 had systemic vasculitis. Fourteen subjects were Caucasian, 13 Asian, 6 East Indian, and 3 Canadian First Nations. An abnormal Z score at one or more sites was found in 10/25 (40%) with JSLE, and in 3/11 (27%) JDM/vasculitis patients. The mean Z scores (+/- SD) for lumbar spine were -1.02 (+/- 1.2), for hip -0.88 (+/- 1.3), and for total body -0.77 (+/- 1.5). Compared to children with normal bone densities, those with lower bone density tended to be younger (13.5 +/- 2.2 vs 15.5 +/- 1.7 yrs), received higher corticosteroid dosages at the time of the study (0.78 +/- 0.6 vs 0.35 +/- 0.2 mg/kg), and were more often prepubertal (OR for total body scores 5, 95% CI 0.7-46).
CONCLUSION: Decreased bone density is common in children with SLE and other systemic rheumatic diseases. Age, corticosteroid dose, and pubertal stage all appear to have some influence on bone mass in these children.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15801032

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  24 in total

1.  Assessment of bone remodelling in childhood-onset systemic lupus erythematosus.

Authors:  Julie C Baker-LePain; Mary C Nakamura; John Shepherd; Emily von Scheven
Journal:  Rheumatology (Oxford)       Date:  2010-11-23       Impact factor: 7.580

2.  Pediatric lupus--are there differences in presentation, genetics, response to therapy, and damage accrual compared with adult lupus?

Authors:  Rina Mina; Hermine I Brunner
Journal:  Rheum Dis Clin North Am       Date:  2010-02       Impact factor: 2.670

3.  Incident vertebral fractures among children with rheumatic disorders 12 months after glucocorticoid initiation: a national observational study.

Authors:  Celia Rodd; Bianca Lang; Timothy Ramsay; Nathalie Alos; Adam M Huber; David A Cabral; Rosie Scuccimarri; Paivi M Miettunen; Johannes Roth; Stephanie A Atkinson; Robert Couch; Elizabeth A Cummings; Peter B Dent; Janet Ellsworth; John Hay; Kristin Houghton; Roman Jurencak; Maggie Larché; Claire LeBlanc; Kiem Oen; Claire Saint-Cyr; Robert Stein; David Stephure; Shayne Taback; Brian Lentle; Maryann Matzinger; Nazih Shenouda; David Moher; Frank Rauch; Kerry Siminoski; Leanne M Ward
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-01       Impact factor: 4.794

Review 4.  Prevalence and burden of pediatric-onset systemic lupus erythematosus.

Authors:  Sylvia Kamphuis; Earl D Silverman
Journal:  Nat Rev Rheumatol       Date:  2010-08-03       Impact factor: 20.543

5.  Combination therapy of rituximab and mycophenolate mofetil in childhood lupus nephritis.

Authors:  Julien Hogan; Astrid Godron; Véronique Baudouin; Theresa Kwon; Jérôme Harambat; Georges Deschênes; Olivier Niel
Journal:  Pediatr Nephrol       Date:  2017-08-05       Impact factor: 3.714

6.  Variable deficits of bone mineral despite chronic glucocorticoid therapy in pediatric patients with inflammatory diseases: a Glaser Pediatric Research Network study.

Authors:  Emily von Scheven; Catherine M Gordon; David Wypij; Marcia Wertz; Kerry T Gallagher; Laura Bachrach
Journal:  J Pediatr Endocrinol Metab       Date:  2006-06       Impact factor: 1.634

Review 7.  Glucocorticoid-induced osteoporosis in rheumatic diseases.

Authors:  Rosa Maria Rodrigues Pereira; Jozélio Freire de Carvalho; Ernesto Canalis
Journal:  Clinics (Sao Paulo)       Date:  2010       Impact factor: 2.365

Review 8.  Chronic pediatric inflammatory diseases: effects on bone.

Authors:  Anuradha Viswanathan; Francisco A Sylvester
Journal:  Rev Endocr Metab Disord       Date:  2007-12-29       Impact factor: 6.514

Review 9.  Long-term bone health in glucocorticoid-treated children with rheumatic diseases.

Authors:  Isabelle Rousseau-Nepton; Bianca Lang; Celia Rodd
Journal:  Curr Rheumatol Rep       Date:  2013-03       Impact factor: 4.592

10.  Bone mineral density reduction in adolescents with systemic erythematosus lupus: association with lack of vitamin D supplementation.

Authors:  M Caetano; M T Terreri; T Ortiz; M Pinheiro; F Souza; R Sarni
Journal:  Clin Rheumatol       Date:  2015-07-31       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.